These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38283729)

  • 1. Remission of Ectopic Cushing Syndrome Secondary to Medullary Thyroid Cancer With Vandetanib and Selpercatinib.
    Jazdarehee A; Abdel-Rahman O; Jacquier JE
    JCEM Case Rep; 2024 Feb; 2(2):luad174. PubMed ID: 38283729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
    Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
    Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
    Nella AA; Lodish MB; Fox E; Balis FM; Quezado MM; Whitcomb PO; Derdak J; Kebebew E; Widemann BC; Stratakis CA
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3055-9. PubMed ID: 24617713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.
    Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
    Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.
    Pitoia F; Bueno F; Schmidt A; Lucas S; Cross G
    Arch Endocrinol Metab; 2015 Aug; 59(4):343-6. PubMed ID: 26331322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medullary Thyroid Cancer with Ectopic Cushing's Syndrome: A Case Report and Systematic Review of Detailed Cases from the Literature.
    Corsello A; Ramunno V; Locantore P; Pacini G; Rossi ED; Torino F; Pontecorvi A; De Crea C; Paragliola RM; Raffaelli M; Corsello SM
    Thyroid; 2022 Nov; 32(11):1281-1298. PubMed ID: 35833793
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful Treatment with Selpercatinib for Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer.
    Ragnarsson O; Piasecka M; Hallqvist A
    Curr Oncol; 2022 May; 29(5):3494-3498. PubMed ID: 35621672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series.
    Koehler VF; Fuss CT; Berr CM; Frank-Raue K; Raue F; Hoster E; Hepprich M; Christ E; Pusl T; Reincke M; Spitzweg C; Kroiss M;
    Clin Endocrinol (Oxf); 2022 Jun; 96(6):847-856. PubMed ID: 34743368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing's syndrome in medullary thyroid carcinoma.
    Sitbon M; Chou P; Bengaly S; Poirot B; Laloi-Michelin M; Deville L; Pachev A; Kowo-Bille A; Dumont C; Chougnet CN
    Eur Thyroid J; 2022 Dec; 11(6):. PubMed ID: 36069795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma.
    Shankar A; Kurzawinski T; Ross E; Stoneham S; Beale T; Proctor I; Hulse T; Simpson K; Gaze MN; Cattaneo E; Gevers E; Marshall L; Hubbard JG; Brain C
    Eur J Cancer; 2021 Oct; 158():38-46. PubMed ID: 34649088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
    Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
    Saltiki K; Simeakis G; Karapanou O; Alevizaki M
    Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
    Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
    Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D898_E901
    Porcelli T; Moccia M; De Stefano MA; Ambrosio R; Capoluongo E; Santoro M; Hadoux J; Schlumberger M; Carlomagno F; Salvatore D
    JCO Precis Oncol; 2023 Aug; 7():e2300052. PubMed ID: 37535881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 18. RET kinase inhibitors for
    Vodopivec DM; Hu MI
    Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Selpercatinib in
    Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
    N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.